2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Looking to invest in an ASX biotech share with the potential to become the next Telix Pharmaceuticals Ltd (ASX: TLX)?

You're not alone!

The S&P/ASX 200 Index (ASX: XJO) biopharmaceutical company has been going from strength to strength lately.

Just in the past few weeks, Telix made several announcements that sent the stock soaring.

First it announced positive results from its ProstACT SELECT clinical cancer trial. And just days later it reported on progress on approval for TLX250-CDx, its kidney cancer imaging agent, with the United States Food and Drug Administration (FDA).

So, just how well have shareholders in this ASX biotech share been faring?

Well, if you'd bought Telix shares one month ago you'd be sitting on a gain of 20% today.

If you'd bought at the start of 2024, you'd be up 78%.

And if you'd snapped up the ASX biotech share for a bargain $1.05 a share five years ago, you'd have watched those shares surge 1,606%.

Or enough to turn a $5,000 investment into $85,300!

Which bring us to Rory Hunter, portfolio manager of SG Hiscock's Medical Technology Fund.

The ASX biotech shares that could mimic Telix's success

The SG Hiscock's Medical Technology Fund will have done well with its Telix Pharmaceuticals holdings.

According to Hunter (courtesy of The Australian Financial Review):

We originally took a position [in Telix] back in 2019 and chief executive Christian Behrenbruch has delivered on all stated commercial milestones in a timely manner, which is a feat not often achieved among early stage biotechs.

Hunter remains moderately bullish on the outlook for the ASX biotech share. But he noted that in the case of this ASX biotech share, "The easy money has been made."

And he cautioned that "investors will need to stomach some volatility" with the Telix share price moving forward.

Though, as you can see on the price chart up top, that's something long-term shareholders in this ASX biotech share should already be well-familiar with.

When asked which stocks his fund holds that have the same explosive potential as Telix or Neuren Pharmaceuticals Ltd (ASX: NEU), Hunter pointed to Clarity Pharmaceuticals Ltd (ASX: CU6) and Dimerix Ltd (ASX: DXB).

He noted that Clarity Pharmaceuticals could replicate "Telix's success in radiotheranostics". While Dimerix could replicate "Neuren's success in rare diseases".

He added that with "assets in late-stage development", Dimerix was a potential M&A target.

Clarity, Hunter added, could also become a potential takeover target for its "exciting and compelling early-stage data".

The Clarity share price is already up a whopping 575% over 12 months.

The Dimerix share price has run even hotter. The ASX biotech share is up 817% over 12 months.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

woman sitting at desk holding hand up in stop motion
Healthcare Shares

Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision

The ASX All Ords stock is awaiting an important announcement from the US FDA.

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

Is the slashed Sonic Healthcare share price a 'buying opportunity'?

Is this stock a healthy opportunity?

Read more »

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.
Healthcare Shares

Buy the ASX 200 healthcare stock with 'decades of growth ahead'

This healthcare giant is well positioned for growth, experts say.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »